Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-BN-PRO
- Development stage
- Phase 1
- Lead developer
- Bavarian Nordic
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MVA-BN-PRO is a recombinant, non-replicating viral vector vaccine based on the Modified Vaccinia Ankara (MVA) platform developed by Bavarian Nordic. The "PRO" suffix typically indicates a prostate cancer-specific construct, where the vector encodes tumor-associated antigens such as prostate-specific antigen (PSA) and/or prostatic acid phosphatase (PAP), designed to stimulate an immune response against prostate cancer cells. The mechanism of action involves delivery of these antigens via the non-replicating MVA vector to induce both humoral and cellular immunity targeting prostate cancer cells expressing PSA or PAP[4]. This approach leverages the safety profile of the MVA platform, which is widely used in other vaccines such as those for smallpox and mpox[1][2][3].
- Other names
- Modified Vaccinia Ankara-Bavarian Nordic PROMVA-BN PRO
02
Targets
PSA (Puromycin-sensitive aminopeptidase)PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on MVA-BN-PRO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-BN-PRO.